Bone infection surgery publication overviews

May 31, 202116:12

This quarter we highlight solutions for bone infection surgery as the Bonalive indication of the quarter. We will share publication overviews with you below.

Cost-Effectiveness Study of One-Stage Treatment of Chronic Osteomyelitis with Bioactive Glass S53P4

The study by Geurts et al. (2019) was set up to evaluate the costs of a one-stage treatment of chronic osteomyelitis using bioactive glass S53P4 versus a two-stage treatment using gentamicin-loaded PMMA beads. The study reveals that one-stage treatment with bioactive glass S53P4 is cost-effective and shows a better clinical outcome. Read the article here.


Efficacy and safety of bioactive glass S53P4 as a treatment for diabetic foot osteomyelitis

In a study by De Giglio et al (2021), the aim was to test the efficacy and safety of S53P4 bioactive glass in treating diabetic foot osteomyelitis. The use of S53P4 bioactive glass was associated with a much lower probability to need additional antibiotic therapy compared to patients treated with traditional procedure, confirming the strong bacterial growth inhibiting feature of S53P4. Read the article here.